European Biotechs Fire up Deals to Develop Parkinson’s Treatments
Last month, European biotechs Ipsen and AC Immune announced multi-million euro deals to acquire or…
12/08/2021 - 4 minutes
Last month, European biotechs Ipsen and AC Immune announced multi-million euro deals to acquire or…
The French pharmaceutical company Ipsen has restarted the dosing of its treatment for a rare…
Pharma and Biotech from every corner flocked to Chicago for the beginning of June. Why?…
Ipsen is paying Exelixis $200M upfront, plus $545M in future milestones to acquire commercialization rights…
Unfortunately, the Biotech world is not only composed of success stories. Active Biotech, a Swedish company…
Canbex, a spin-off of University College London (UCL) that raised a Series A financing of…